United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg - tizanidine is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1)]. tizanidine is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions (7.1, 7.2)]. 8.1 pregnancy pregnancy category c tizanidine has not been studied in pregnant women. tizanidine should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity. tizanidine at doses that are equal to and up to 8 times the maximum recommended human dose on a mg/m2 basis

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine tablets are a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine tablets should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1)] . tizanidine is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions (7.1, 7.2)]. pregnancy category c tizanidine has not been studied in pregnant women. tizanidine should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity. tizanidine at doses that are equal to and up to 8 times the maximum recommended human dose on a mg/m2 basis

United States - English - NLM (National Library of Medicine)

quality care products llc - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - indications and usage tizanidine tablets are a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). contraindications concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2, cmax, increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions ). tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients.

United States - English - NLM (National Library of Medicine)

clinical solutions wholesale - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg - tizanidine tablets usp is a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine tablets usp should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t 1/2 , c max , increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology, drug interactions ). tizanidine is contraindicated in patients with known hypersensitivity to tizanidine or its ingredients. abuse potential was not evaluated in human studies. rats were able to distinguish tizanidine from sal

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine hydrochloride capsules are central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1)] . tizanidine hydrochloride is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions (7.1, 7.2)]. pregnancy category c tizanidine hydrochloride has not been studied in pregnant women. tizanidine hydrochloride should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity. tizanidine at doses that are equa

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine hydrochloride is indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1)] . tizanidine hydrochloride capsules are contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions (7.1, 7.2)]. risk summary there are no adequate data on the developmental risk associated with use of tizanidine in pregnant women. in animal studies, administration of tizanidine during pregnancy resulted in developmental toxicity (embryofetal and postnatal offspring mortality and growth deficits) at doses less than those used clinically, which were not associated with maternal toxicity (see animal data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies